

RESEARCH PEPTIDE

KLOW

BPC-157 + TB4 + GHK-Cu + KPV

Comprehensive Recovery & Skin Health

Four-peptide research blend studied for complementary tissue-repair, skin-regeneration, collagen and inflammation-related pathways.



RESEARCH
TODAY



DISCOVER
TOMORROW



A HEALTHIER
HUMAN POTENTIAL



SCIENCE
INSPIRES
HUMAN
POTENTIAL



WHAT IS KLOW AND WHY IS IT STUDIED?

KLOW combines BPC-157, TB4, GHK-Cu and KPV in an 80 mg blend. It is studied for complementary roles in tissue repair, skin regeneration, collagen activity, inflammation-related recovery and gut-barrier support. The individual components are commonly researched in wound-healing, connective-tissue, skin-quality and regenerative models.



AT A GLANCE

 80 mg vial



Research focus: tissue repair, skin regeneration, collagen support, inflammation-response and gut-barrier research



Format: lyophilized powder



WHAT IT IS STUDIED FOR

- Tissue repair and wound-healing models
- Skin regeneration and collagen support
- Inflammation-response research
- Gut and barrier-function research
- Tendon, ligament and muscle recovery
- Scar appearance and tissue remodeling
- Hair/follicle and tissue-health studies



HOW IT MAY WORK

- BPC-157: localized repair signaling in tendon, ligament, muscle and GI models
- TB4: cell migration, angiogenesis and tissue-regeneration pathways
- GHK-Cu: collagen activity, tissue remodeling and skin/follicle support
- KPV: anti-inflammatory and gut-protective pathways
- **Together:** complementary repair, skin and inflammation-related effects



WHAT RESEARCHERS MAY LOOK FOR OVER TIME

1-2 WEEKS

Track tolerability, injection-site response, and early inflammation or recovery markers.

WEEKS 3-6

Assess tissue-repair and recovery markers, plus early skin hydration or texture changes.

WEEKS 6-12

Evaluate collagen, skin quality, scar appearance, connective-tissue and hair/follicle endpoints.

WEEKS 12-16

Assess cumulative recovery and skin/tissue-health endpoints before the source-recommended 2-4 week break.



80 MG RESEARCH PROTOCOL

Reconstitution	3 mL bacteriostatic water / No Sting Water
Final concentration	80 mg / 3 mL = 26.7 mg/mL total blend
Source dose	0.5 mg BPC-157 + 0.5 mg TB4 + 2.5 mg GHK-Cu + 0.5 mg KPV
Syringe reference	15 units
Frequency	3x per week
Research duration	12-16 weeks
Break	2-4 weeks
Administration (as in source)	SubQ injection
Notes	May sting; use No Sting Water. GHK-Cu is 2.5 mg per source dose. Source cautions against higher copper exposure; additional BPC-157/TB4 may be studied separately.



MIXING

80 mg + 3 mL BAC / No Sting Water = 26.7 mg/mL

15 units = 0.5 mg BPC-157 + 0.5 mg TB4 + 2.5 mg GHK-Cu + 0.5 mg KPV



TITRATION

No dose-escalation schedule is provided in the source protocol. The source uses 15 units, three times per week. GHK-Cu is 2.5 mg per source dose.



IMPORTANT CONSIDERATIONS

- For educational and research purposes only
- Limited blend-specific human data
- Avoid use in active or recent cancer research subjects
- Not recommended during pregnancy or breastfeeding
- Store appropriately after reconstitution



EVIDENCE LEVEL

- Blend-specific human research — Limited
- Component literature — Variable
- Mechanistic evidence — Emerging
- Long-term blend safety — Limited



RESEARCH USE DISCLAIMER

For educational and research use only. Not for human use. Not approved by the FDA or any other regulatory authority. Research compounds are not intended for diagnosis, treatment, or prevention of any disease.